Intravitreal bevacizumab for myopic choroidal neovascularization: 1-year and 2-year results.
A retrospective interventional case series of 29 patients with mCNV was conducted. Charts were reviewed of all patients who received IVB for active mCNV and who had a follow-up of at least 12 months after the first injection. Patients were divided into three groups based on length of followup: patients in Group 1 had a follow-up of > or =12 months, in Group 2 of > or =18 months and in Group 3 of > or =24 months. Changes in visual acuity (VA) and CMT were analyzed, as were safety considerations such as intraocular inflammation and endophthalmitis. Twenty women and nine men with a mean age of 62.2 years (range 31-85) were included. No peri- or post-injection ocular or systemic side effects were noted in either group. Mean logMAR best-corrected visual acuity (BCVA) at baseline for all patients (n=29) was 0.71. Mean visual acuity for all 29 patients had improved significantly at 3 months (p = 0.0035) and one year (p = 0.0042) after baseline. Although visual acuity gains were maintained at 18 and 24 months, these were not statistically significant (p = 0.11 and p = 0.19, respectively). The mean CMT decreased significantly at one year after baseline. This study confirms that administration of intravitreal bevacizumab is a safe and effective treatment modality for mCNV. Statistically significant visual improvement can be obtained.